Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrodotoxin for Chemotherapy Induced Neuropathic Pain
NCT05359133Phase 2Terminated
- Sponsor
- Dogwood Therapeutics, Inc.
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tetrodotoxin in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Dogwood Therapeutics, Inc.. Started Apr 2022; status: terminated.
02
Drugs
tetrodotoxin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05359133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359133.